Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
Germany
Universitätsklinikum Bonn, Bonn University Hospital Freiburg, Neurosurgery, Freiburg im Breisgau University Hospital Heidelberg, Neurooncology, Heidelberg SLK-Kliniken Heilbronn GmbH Klinik, Heilbronn University Hospital Mannheim, Neurology Clinic, Mannheim